Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
C-Met
100%
Metastatic Breast Cancer
100%
Triple-negative Breast Cancer
100%
Dual Inhibitor
100%
Doxazosin
100%
Apoptosis
20%
Stem Cells
20%
Therapeutic Potential
20%
Molecular Docking Studies
20%
Triple-negative Breast Cancer Cells
20%
Tumor Growth
10%
Overexpression
10%
High Cost
10%
Toxic Effects
10%
Treatment Options
10%
Metastasis
10%
Cell Viability
10%
Antiproliferative Activity
10%
Cancer Stem Cells
10%
MEK-ERK
10%
Tumor Angiogenesis
10%
Tumoral
10%
Direct Interaction
10%
Renal Function
10%
EGFR Inhibitors
10%
Metastatic Models
10%
Breast Cancer Cell Lines
10%
Caspase Activation
10%
Survival Pathways
10%
Benign Prostatic Hyperplasia
10%
3rd Generation
10%
Tyrosine Kinase Domain
10%
Distant Metastasis
10%
MET Inhibitor
10%
Aldehyde Dehydrogenase 2 (ALDH2)
10%
Unfavorable Outcome
10%
Promising Treatment
10%
Hepatic Function
10%
Mammosphere
10%
Peritumoral
10%
Metastatic Triple-negative Breast Cancer
10%
Allograft Model
10%
Aggressive Growth
10%
EGFR Signaling Pathway
10%
JAK-STAT3
10%
Generic Drugs
10%
Docking Impact
10%
Immunology and Microbiology
Cancer Stem Cell
100%
Molecular Docking
66%
Signal Transduction
33%
Caspase
33%
Cancer Cell
33%
Angiogenesis
33%
Cell Viability
33%
Antiproliferative Activity
33%
Prostate
33%
STAT3
33%
Breast Cancer Cell Line
33%
Kidney Function
33%
Liver Function
33%
Allograft
33%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Metastasis
100%
Triple Negative Breast Cancer
100%
Doxazosin
100%
Malignant Neoplasm
30%
Tumor Growth
10%
Caspase
10%
Toxicity
10%
Cell Viability
10%
Protein Tyrosine Kinase
10%
Recurrent Disease
10%
Prostate Hypertrophy
10%
Distant Metastasis
10%
Aldehyde Dehydrogenase Isoenzyme 1
10%
Generic Drug
10%
Biochemistry, Genetics and Molecular Biology